ArticleProstate international2025
Postoperative tadalafil for recovery of continence and voiding function after radical prostatectomy for prostate cancer: a single-center experience.
Article in Prostate international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the impact of postoperative tadalafil on the recovery of erectile function, voiding function, and urinary continence in patients undergoing radical prostatectomy (RP) for prostate cancer. Materials and methods: A retrospective analysis was conducted on 4,173 patients who underwent RP. Patients were categorized based on postoperative use of tadalafil. Functional outcomes were assessed using the International Index of Erectile Function (IIEF-5) and the International Prostate Symptom Score (IPSS), along with continence status and oncologic parameters. Statistical analyses included chi-square and t-tests. Results: In the final cohort, 916 patients received postoperative tadalafil and were compared to 3,257 patients without any phosphodiesterase type 5 (PDE5) inhibitor therapy. While early postoperative erectile function was lower in the tadalafil cohort at 1 month, recovery was superior by 12 months (IIEF-5: 5.9 ± 5.5 vs. 4.8 ± 5.6, p = 0.002). Voiding function also declined less markedly postoperatively (IPSS increase: 1.4 vs. 2.4 points), with significant improvement maintained through 12 months. Social continence rates were higher in the tadalafil group (95.1% vs. 92.6 %, p = 0.009), and biochemical recurrence was lower (11.7% vs. 25.7%, p < 0.001). Conclusions: Postoperative tadalafil is associated with improved recovery of erectile and voiding function, as well as higher continence rates, without compromising oncologic outcomes. These findings support its consideration as part of routine postoperative management in selected RP patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.